Difference between revisions of "Treosulfan (Ovastat)"
Jump to navigation
Jump to search
(Created page with "==General information== Class/mechanism: Bifunctional alkylating agent which produces guanine-adenine intrastrand crosslinks, inducing apoptosis. <br>Route: IV, PO <br>Extrava...") |
m |
||
| Line 6: | Line 6: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Ovarian cancer]] | *[[Ovarian cancer]] | ||
| + | |||
| + | ==History of changes in EMA indication== | ||
| + | *6/20/2019: Initial authorization | ||
| + | *Treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients with malignant and non malignant diseases, and in paediatric patients older than one month with malignant diseases. | ||
==Also known as== | ==Also known as== | ||
| Line 16: | Line 20: | ||
[[Category:Ovarian cancer medications]] | [[Category:Ovarian cancer medications]] | ||
| + | |||
| + | [[Category:EMA approved in 2019]] | ||
Revision as of 13:27, 3 January 2023
General information
Class/mechanism: Bifunctional alkylating agent which produces guanine-adenine intrastrand crosslinks, inducing apoptosis.
Route: IV, PO
Extravasation: irritant
Diseases for which it is used
History of changes in EMA indication
- 6/20/2019: Initial authorization
- Treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients with malignant and non malignant diseases, and in paediatric patients older than one month with malignant diseases.
Also known as
- Brand names: Ovastat, Trecondi